Understanding pancreatic neuroendocrine tumors through protein analysis
Official title: Proteomic Characterization of Pancreatic Neuroendocrine Tumors and Metastatic Progression
Funded at Beth Israel Deaconess Medical Center · NIH-10907222 · Data updated 2026-11-12
This study is looking at pancreatic neuroendocrine tumors to find out more about their different types by examining the proteins in the tumors, which could help doctors better understand how to treat patients based on their risk of spreading the cancer.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 20, 2021 |
| Project end | July 31, 2025 |
| Funding year | 2022 |
| Award (this year) | $218,824 |
| NIH project number | 7R21CA263262-03 |
| Project ID | NIH-10907222 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic neuroendocrine tumors, particularly those who have undergone surgical resection.
✕Less likely to help
Patients with other types of pancreatic tumors or those who have not been diagnosed with pancreatic neuroendocrine tumors may not benefit from this research.
What this research studies
This research investigates pancreatic neuroendocrine tumors (PanNETs) by analyzing their protein profiles to identify different subtypes that may explain variations in patient outcomes. The study aims to uncover new classifications of these tumors using deep proteomic analysis, which could lead to better risk stratification and monitoring strategies. By comparing tissues from patients with low and high risk of metastasis, the research seeks to establish protein markers that could aid in early detection and treatment response. This approach may provide insights that traditional genomic methods have not achieved.
Why it matters
Potential benefit: If successful, this research could lead to improved classification and monitoring of pancreatic neuroendocrine tumors, potentially enhancing treatment outcomes for patients.
How similar studies have gone: Preliminary studies have shown success in using proteomic profiling to distinguish and subclassify various tumors, indicating a promising approach for this research.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Roehrl, Michael H. a. — Beth Israel Deaconess Medical Center
- Study coordinator: Roehrl, Michael H. a.
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Enteric glial cell reprogramming and MENIN loss in dpNETs
A study to understand how losing a gene called MENIN in gut-supporting glial cells might turn them into neuroendocrine tumor cells in people with MEN1.
-
Targeting CXCR4 and redox metabolism to treat lung neuroendocrine cancers with targeted alpha therapy
Aims to develop a new alpha-particle therapy approach for hard-to-treat lung neuroendocrine tumors by attacking CXCR4 and redox pathways.
-
Optimizing Theranostic Dosimetry and Kidney Biomarkers for Alpha-Emitter Radioligand Therapy in Neuroendocrine Tumors
This project tests a new targeted radiotherapy approach for neuroendocrine tumors to maximize tumor response while protecting kidneys.
-
SSTR2 imaging to guide pituitary tumor radiotherapy and planning
This project tests a PET/MRI imaging approach to map somatostatin receptor 2 in pituitary neuroendocrine tumors to help tailor radiation therapy for better tumor control.
-
Chromatin biomarkers linked to prognosis in non-functional pancreatic neuroendocrine tumors
A study exploring chromatin-related biomarkers to better predict which non-functional pancreatic neuroendocrine tumors may behave aggressively.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.